SCHEMBL345583

SCHEMBL345583

CC(C)(C)OC(=O)NCCCCCC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.69
MEN1 O00255 1/20 0.60
GAA P10253 1/20 0.60
KMT2A Q03164 1/20 0.60
MAOA P21397 1/20 0.59
MAOB P27338 1/20 0.59
ADRA1A P35348 1/20 0.56
CA12 O43570 5/20 0.55
CA1 P00915 5/20 0.55
CA2 P00918 5/20 0.55
CA9 Q16790 5/20 0.55
PRMT1 Q99873 1/20 0.55
CYP3A4 P08684 1/20 0.49
EPHX2 P34913 2/20 0.48
PLA2G2A P14555 1/20 0.47
CHRM2 P08172 2/20 0.47
CHRM4 P08173 2/20 0.47
CHRM5 P08912 2/20 0.47
CHRM1 P11229 2/20 0.47
CHRM3 P20309 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1931146 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL826755 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL7911543 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL826376 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL826329 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL2702010 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL16487196 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL22276615 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL22276602 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA
SCHEMBL8002115 1.00 TDP1 (0.69) TDP1MEN1GAAKMT2AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1915 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250352656-A1 SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS PEPTOMER THERAPEUTICS PRIVATE LTD (IN) 2025-11-20 US claimed
CN-119912435-A Nanoparticle for treating pulmonary diseases and preparation method and application thereof 北京师范大学 2025-05-02 CN claimed
EP-4525827-A1 SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS Peptomer Therapeutics Private Limited (IN) 2025-03-26 EP claimed
CN-118987237-A Amphiphilic functional nano-composite and preparation method and application thereof 河南中医药大学 2024-11-22 CN claimed
CN-118619952-A Aloperine derivative, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-09-10 CN claimed
US-20240285575-A1 NANOPARTICLES WITH ANTI-INFLAMMATORY PROPERTIES AND ENHANCED PENETRATION ACROSS THE BIOLOGICAL BARRIERS TO DELIVER ENCAPSULATED DRUGS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 2024-08-29 US claimed
CN-118206612-A Ocotill type sapogenin A cycloaminothiazole ring derivative and preparation method and application thereof 烟台大学 2024-06-18 CN claimed
CN-117801041-A Preparation method and application of coumarin derivative labeled nucleoside triphosphate 广州安必平医药科技股份有限公司 2024-04-02 CN claimed
CN-117362387-A Benzenesulfonamide piperazinone glycine derivative as well as preparation method and application thereof 山东大学 2024-01-09 CN claimed
CN-117264925-A Modified enzymes 牛津纳米孔科技公开有限公司 2023-12-22 CN claimed
CN-106349335-A Targeting antitumor drug and synthesizing method thereof 北京化工大学 2017-01-25 CN claimed
US-20120178783-A1 HDAC INHIBITORS LIXTE BIOTECHNOLOGY, INC. 2012-07-12 US claimed
US-8143445-B2 HDAC inhibitors LIXTE BIOTECHNOLOGY, INC. (US) 2012-03-27 US claimed
EP-2200439-A1 HDAC INHIBITORS Lixte Biotechnology, Inc. (US) 2010-06-30 EP claimed
US-20090143445-A1 HDAC Inhibitors JOHN P. WHITE, ESQ 2009-06-04 US claimed
WO-2009045440-A1 HDAC INHIBITORS LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) 2009-04-09 WO claimed
US-20050049306-A1 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same HARPER DAVID SCOTT (US) 2005-03-03 US claimed
US-20040010046-A1 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same MCNEIL-PPC, INC 2004-01-15 US claimed
US-20020110530-A1 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same HARPER DAVID SCOTT (US) 2002-08-15 US claimed
US-6004823-A Compounds SMITHKLINE BEECHAM CORPORATION (US) 1999-12-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178783-A1 HDAC INHIBITORS HDAC3, HDAC4, HDAC7 TDP1 3530/4885MEN1 2353/4885GAA 4142/4885
US-20250352656-A1 SYNTHETIC CATIONIC PEPTIDOMIMETICS, THEIR DERIVATIVES AND PREPARATION THEREOF ALONG WITH COMPOSITIONS FOR VARIOUS MEDICAL APPLICATIONS NOD2, NGLY1, CGAS TDP1 1294/4885MEN1 583/4885GAA 341/4885
US-20050049306-A1 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same NPM1, NOC2L, NAF1 TDP1 3744/4885MEN1 2321/4885GAA 1523/4885
US-20040010046-A1 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same NPM1, NOC2L, NAF1 TDP1 3744/4885MEN1 2321/4885GAA 1523/4885
US-20090143445-A1 HDAC Inhibitors HDAC3, HDAC7, HDAC4 TDP1 3480/4885MEN1 2360/4885GAA 4109/4885
US-20020110530-A1 Non-halogenated naphthol compounds, antimicrobial compositions containing the same, and methods of using the same NPM1, NOC2L, NAF1 TDP1 3744/4885MEN1 2321/4885GAA 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.